Related Experiment Video
Updated: Jul 27, 2026
05:31
Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
Differences in microsatellite DNA level between asthma and chronic obstructive pulmonary disease.
M I Zervou1, E G Tzortzaki, D Makris
1Research Laboratory of Molecular Pulmonology, University of Crete Medical School, Iráklion, Greece.
The European Respiratory Journal
|May 19, 2006
Summary
Microsatellite DNA instability (MSI) is more frequent in chronic obstructive pulmonary disease (COPD) than in asthma. This DNA-level difference may help distinguish between these respiratory conditions, though further research is needed.
Area of Science:
- Pulmonary Medicine
- Genetics
- Molecular Biology
Background:
- Microsatellite (MS) DNA instability (MSI) has been observed in sputum cells of patients with chronic obstructive pulmonary disease (COPD) and asthma.
- Distinguishing between COPD and asthma at the DNA level could offer novel diagnostic insights.
Purpose of the Study:
- To investigate if asthma and COPD can be differentiated based on microsatellite DNA instability patterns.
- To analyze MSI in sputum and white blood cells of patients with COPD, asthma, non-COPD smokers, and healthy individuals.
Main Methods:
- DNA was extracted from sputum and white blood cells of 63 COPD patients, 60 non-COPD smokers, 36 asthmatics, and 30 healthy controls.
- Ten microsatellite markers across seven chromosomes were analyzed for instability.
- Microsatellite instability was quantified and compared between the different study groups.
Main Results:
- No MSI was detected in healthy non-smokers or non-COPD smokers.
- A significantly higher proportion of COPD patients (49.2%) exhibited MSI compared to asthmatics (22.2%).
- Specific markers (D6S344, G29802, D13S71) showed alterations exclusively in COPD, with G29802 linked to decreased FEV1 and D6S344 to increased FEV1.
Conclusions:
- Microsatellite DNA instability occurs more frequently in COPD than in asthma.
- Certain MSI markers demonstrate potential for distinguishing COPD from asthma.
- Further research is required to validate these findings and explore the clinical utility of MSI in differentiating respiratory diseases.
Related Concept Videos
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...